Actavis launches Valaciclovir in Switzerland
This article was originally published in Scrip
Executive Summary
Actavis has launched a generic version of GlaxoSmithKline's herpes virus therapy valaciclovir 500 mg tablets (Valtrex and Zelitrex) in Switzerland under its own brand, Valaciclovir Actavis. GSK's patent for the product there expired on 27 June. Medis, Actavis's third-party sales division, launched the product simultaneously.